291 related articles for article (PubMed ID: 31555275)
21. Hepatocyte expression of TRAIL pathway regulators correlates with histopathological and clinical parameters in chronic HCV infection.
Brost S; Zimmermann A; Koschny R; Sykora J; Stremmel W; Schirmacher P; Walczak H; Ganten TM
Pathol Res Pract; 2014 Feb; 210(2):83-91. PubMed ID: 24268735
[TBL] [Abstract][Full Text] [Related]
22. Design, selection and optimization of an anti-TRAIL-R2/anti-CD3 bispecific antibody able to educate T cells to recognize and destroy cancer cells.
Satta A; Mezzanzanica D; Caroli F; Frigerio B; Di Nicola M; Kontermann RE; Iacovelli F; Desideri A; Anichini A; Canevari S; Gianni AM; Figini M
MAbs; 2018 Oct; 10(7):1084-1097. PubMed ID: 29993310
[TBL] [Abstract][Full Text] [Related]
23. Surface TRAIL decoy receptor-4 expression is correlated with TRAIL resistance in MCF7 breast cancer cells.
Sanlioglu AD; Dirice E; Aydin C; Erin N; Koksoy S; Sanlioglu S
BMC Cancer; 2005 May; 5():54. PubMed ID: 15916713
[TBL] [Abstract][Full Text] [Related]
24. Zoledronate facilitates large-scale ex vivo expansion of functional gammadelta T cells from cancer patients for use in adoptive immunotherapy.
Kondo M; Sakuta K; Noguchi A; Ariyoshi N; Sato K; Sato S; Sato K; Hosoi A; Nakajima J; Yoshida Y; Shiraishi K; Nakagawa K; Kakimi K
Cytotherapy; 2008; 10(8):842-56. PubMed ID: 19016372
[TBL] [Abstract][Full Text] [Related]
25. In vitro analysis of the proliferative capacity and cytotoxic effects of ex vivo induced natural killer cells, cytokine-induced killer cells, and gamma-delta T cells.
Niu C; Jin H; Li M; Xu J; Xu D; Hu J; He H; Li W; Cui J
BMC Immunol; 2015 Oct; 16():61. PubMed ID: 26458364
[TBL] [Abstract][Full Text] [Related]
26. Genetically Induced Tumors in the Oncopig Model Invoke an Antitumor Immune Response Dominated by Cytotoxic CD8β
Overgaard NH; Principe DR; Schachtschneider KM; Jakobsen JT; Rund LA; Grippo PJ; Schook LB; Jungersen G
Front Immunol; 2018; 9():1301. PubMed ID: 29930558
[TBL] [Abstract][Full Text] [Related]
27. Expression of TRAIL receptors in human autoreactive and foreign antigen-specific T cells.
Wendling U; Walczak H; Dörr J; Jaboci C; Weller M; Krammer PH; Zipp F
Cell Death Differ; 2000 Jul; 7(7):637-44. PubMed ID: 10889508
[TBL] [Abstract][Full Text] [Related]
28. [Effect of zoledronate on the cytotoxicity of γδ T cells from PBMCs of osteosarcoma patients against osteosarcoma].
Li Z; Tang J; Sun L; Ye Z
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2013 Jan; 29(1):6-9. PubMed ID: 23294710
[TBL] [Abstract][Full Text] [Related]
29. Negative control of TRAIL-R1 signaling by transforming growth factor β1 in pancreatic tumor cells involves Smad-dependent down regulation of TRAIL-R1.
Radke DI; Ungefroren H; Helm O; Voigt S; Alp G; Braun H; Hübner S; Dilchert J; Sebens S; Adam D; Kalthoff H; Trauzold A
Cell Signal; 2016 Nov; 28(11):1652-62. PubMed ID: 27492861
[TBL] [Abstract][Full Text] [Related]
30. Galectin-3 Released by Pancreatic Ductal Adenocarcinoma Suppresses γδ T Cell Proliferation but Not Their Cytotoxicity.
Gonnermann D; Oberg HH; Lettau M; Peipp M; Bauerschlag D; Sebens S; Kabelitz D; Wesch D
Front Immunol; 2020; 11():1328. PubMed ID: 32695112
[TBL] [Abstract][Full Text] [Related]
31. Tumor-infiltrating IL-17-producing gammadelta T cells support the progression of tumor by promoting angiogenesis.
Wakita D; Sumida K; Iwakura Y; Nishikawa H; Ohkuri T; Chamoto K; Kitamura H; Nishimura T
Eur J Immunol; 2010 Jul; 40(7):1927-37. PubMed ID: 20397212
[TBL] [Abstract][Full Text] [Related]
32. High TRAIL-R3 expression on leukemic blasts is associated with poor outcome and induces apoptosis-resistance which can be overcome by targeting TRAIL-R2.
Chamuleau ME; Ossenkoppele GJ; van Rhenen A; van Dreunen L; Jirka SM; Zevenbergen A; Schuurhuis GJ; van de Loosdrecht AA
Leuk Res; 2011 Jun; 35(6):741-9. PubMed ID: 21281967
[TBL] [Abstract][Full Text] [Related]
33. CD16+ gammadelta T cells mediate antibody dependent cellular cytotoxicity: potential mechanism in the pathogenesis of multiple sclerosis.
Chen Z; Freedman MS
Clin Immunol; 2008 Aug; 128(2):219-27. PubMed ID: 18501678
[TBL] [Abstract][Full Text] [Related]
34. Receptors and lytic mediators regulating anti-tumor activity by the leukemic killer T cell line TALL-104.
Brando C; Mukhopadhyay S; Kovacs E; Medina R; Patel P; Catina TL; Campbell KS; Santoli D
J Leukoc Biol; 2005 Aug; 78(2):359-71. PubMed ID: 15937142
[TBL] [Abstract][Full Text] [Related]
35. Differential localization and regulation of death and decoy receptors for TNF-related apoptosis-inducing ligand (TRAIL) in human melanoma cells.
Zhang XD; Franco AV; Nguyen T; Gray CP; Hersey P
J Immunol; 2000 Apr; 164(8):3961-70. PubMed ID: 10754286
[TBL] [Abstract][Full Text] [Related]
36. Decoy receptor-2 small interfering RNA (siRNA) strategy employing three different siRNA constructs in combination defeats adenovirus-transferred tumor necrosis factor-related apoptosis-inducing ligand resistance in lung cancer cells.
Aydin C; Sanlioglu AD; Karacay B; Ozbilim G; Dertsiz L; Ozbudak O; Akdis CA; Sanlioglu S
Hum Gene Ther; 2007 Jan; 18(1):39-50. PubMed ID: 17187448
[TBL] [Abstract][Full Text] [Related]
37. Tumor-infiltrating CD4+ T lymphocytes express APO2 ligand (APO2L)/TRAIL upon specific stimulation with autologous lung carcinoma cells: role of IFN-alpha on APO2L/TRAIL expression and -mediated cytotoxicity.
Dorothée G; Vergnon I; Menez J; Echchakir H; Grunenwald D; Kubin M; Chouaib S; Mami-Chouaib F
J Immunol; 2002 Jul; 169(2):809-17. PubMed ID: 12097384
[TBL] [Abstract][Full Text] [Related]
38. Nuclear death receptor TRAIL-R2 inhibits maturation of let-7 and promotes proliferation of pancreatic and other tumor cells.
Haselmann V; Kurz A; Bertsch U; Hübner S; Olempska-Müller M; Fritsch J; Häsler R; Pickl A; Fritsche H; Annewanter F; Engler C; Fleig B; Bernt A; Röder C; Schmidt H; Gelhaus C; Hauser C; Egberts JH; Heneweer C; Rohde AM; Böger C; Knippschild U; Röcken C; Adam D; Walczak H; Schütze S; Janssen O; Wulczyn FG; Wajant H; Kalthoff H; Trauzold A
Gastroenterology; 2014 Jan; 146(1):278-90. PubMed ID: 24120475
[TBL] [Abstract][Full Text] [Related]
39. mTOR inhibition potentiates cytotoxicity of Vγ4 γδ T cells via up-regulating NKG2D and TNF-α.
Cao G; Wang Q; Li G; Meng Z; Liu H; Tong J; Huang W; Liu Z; Jia Y; Wei J; Chi H; Yang H; Zhao L; Wu Z; Hao J; Yin Z
J Leukoc Biol; 2016 Nov; 100(5):1181-1189. PubMed ID: 27256566
[TBL] [Abstract][Full Text] [Related]
40. γδ T cell activation by bispecific antibodies.
Oberg HH; Kellner C; Gonnermann D; Peipp M; Peters C; Sebens S; Kabelitz D; Wesch D
Cell Immunol; 2015 Jul; 296(1):41-9. PubMed ID: 25979810
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
